Tetraphase Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TETRAPHASE PHARMS, and what generic alternatives to TETRAPHASE PHARMS drugs are available?
TETRAPHASE PHARMS has one approved drug.
There are four US patents protecting TETRAPHASE PHARMS drugs.
There are seventy-four patent family members on TETRAPHASE PHARMS drugs in thirty-three countries and seventeen supplementary protection certificates in fifteen countries.
Summary for Tetraphase Pharms
| International Patents: | 74 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Tetraphase Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | 8,796,245 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | 10,961,190 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | 8,906,887 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | 8,796,245 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tetraphase Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2323972 | ⤷ Subscribe |
| Spain | 2430254 | ⤷ Subscribe |
| Japan | 2011530534 | ⤷ Subscribe |
| New Zealand | 624272 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tetraphase Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2323972 | 132019000000039 | Italy | ⤷ Subscribe | PRODUCT NAME: ERAVACICLINA DICLORIDRATO(XERAVA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1312, 20180924 |
| 2323972 | CR 2019 00009 | Denmark | ⤷ Subscribe | PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209 |
| 2323972 | PA2019009 | Lithuania | ⤷ Subscribe | PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920 |
| 2323972 | LUC00107 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: ERAVACYCLINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
